Acute myeloid leukemia: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - " ==" to "==") |
(Text replacement - "*CXR" to "*CXR") |
||
| Line 13: | Line 13: | ||
==Evaluation== | ==Evaluation== | ||
*CXR | *[[CXR]] | ||
*CBC with peripheral smear | *CBC with peripheral smear | ||
*Chem7, ca, mg, phos, Uric Acid, UA, LDH (to check for Tumor Lysis) | *Chem7, ca, mg, phos, Uric Acid, UA, LDH (to check for Tumor Lysis) | ||
Revision as of 10:00, 9 September 2016
Background
- aka Acute myelogenous leukemia or non-lymphocytic leukemia
- Most common acute leukemia in adults (around 80% of cases)
- 65yo median age of diagnosis, Male:Female 5:3
- characterized by clonal proliferation of myeloid precursors(blast cells >20% in the periphery)
Clinical Features
- Presents with anemia, neutropenia, thrombocytopenia,
- weakness, easy fatigability, infections, gingival bleeding/enlargement, ecchymoses, epistaxis, menorrhagia
Differential Diagnosis
Acute Leukemia/Lymphoma
Evaluation
- CXR
- CBC with peripheral smear
- Chem7, ca, mg, phos, Uric Acid, UA, LDH (to check for Tumor Lysis)
- LFTs, Coags, FDP, D-Dimer, Haptoglobin, Fibrinogen (to check for DIC)
- Get extra purple top for flow cytometry, especially before transfusion
Treatment
- Aggressive IV hydration
- If febrile, complete cultures and broad spectrum antibiotics
- Manage Complications
- see DIC
- see Leukostasis
- see Tumor Lysis Syndrome
- see Retinoic acid syndrome